The Council of the European Union on 2 December 2026 published a Commission report summarising Member States' implementation of Directive 2009/41/EC on the contained use of genetically modified micro-organisms (GMMs) for the period 2022-2024. The report finds stable implementation across the EU, with several Member States introducing digital notification systems for contained use activities. However, it notes challenges in interpreting the Directive due to the emergence of new genomic techniques (NGTs), which may blur the line between contained use and deliberate release.
The report, issued as a Council cover note, is a mandatory assessment under Article 10 of Directive 2009/41/EC. It covers the 2022-2024 reporting period and is based on national reports submitted by Member States. The document is a factual summary and does not propose legislative changes, but it flags areas where the Directive may need updating to keep pace with scientific developments.
Policy Orientations and Trade-offs The report highlights a trade-off between biosafety and innovation. On one hand, digital notification systems improve efficiency and traceability, reducing administrative burdens for both industry and regulators. On the other hand, the rise of NGTs—such as CRISPR-based gene editing—poses challenges for classification: some NGT-derived organisms may fall under the Directive's scope, but their risk assessment is less straightforward. This creates a cleavage between biosafety precaution (requiring strict oversight) and innovation facilitation (seeking lighter regulation for NGTs). The report does not resolve this tension but calls for clearer guidance.
Impact on Stakeholders - EU regulatory bodies: The European Commission and the European Food Safety Authority may need to update guidance documents to address NGTs, potentially increasing their workload. - National authorities: Member States face pressure to harmonise interpretation of the Directive, especially regarding NGTs, which could require additional training and resources. - Industry (biotech and pharma sectors): Companies using GMMs in R&D benefit from digitalisation (faster notifications) but face uncertainty about whether NGT-derived organisms will be subject to the same containment rules, affecting investment decisions. - Civil society and environmental NGOs: They may push for maintaining strict oversight to prevent accidental release, arguing that NGTs pose unknown risks.
Expected Institutional Follow-up The report is for information and does not trigger immediate legislative action. However, it may inform future Commission proposals to revise Directive 2009/41/EC, particularly in light of ongoing discussions on NGT regulation. The European Parliament and Council may request further impact assessments or guidance documents. The next implementation report is due in 2027.
← Atlas › News › Environment